Surgery for Men with Breast Cancer: Do the Same Data Still Apply?
Breast radiation
Breast surgery
Local–regional therapy
Male breast cancer
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
25
05
2020
accepted:
30
06
2020
pubmed:
25
7
2020
medline:
5
5
2021
entrez:
25
7
2020
Statut:
ppublish
Résumé
Men represent a small proportion of breast cancer diagnoses, and they are often excluded from clinical trials. Current treatments are largely extrapolated from evidence in women. We compare practice patterns between men and women with breast cancer following the publication of several landmark clinical trials in surgery. Patients with invasive breast cancer (2004-2015) from the National Cancer Data Base were identified; subcohorts were created based on eligibility for NSABP-B06, CALGB 9343, and ACOSOG Z0011. Practice patterns were stratified by gender and compared. Cox proportional hazards regression analyses were utilized to estimate the association between OS and gender. Of the 1,664,746 patients identified, 99% were women and 1% were men. Among NSABP-B06 eligible men, mastectomy rates did not change (consistently ~ 80%), and their adjusted OS was minimally worse compared with women (HR 1.19, 95% CI 1.11-1.28). Following publication of CALGB 9343, omission of radiation after lumpectomy was less likely in men and lagged behind that of women, despite similar OS (male HR 0.92, 95% CI 0.59-1.44). Application of ACOSOG Z0011 findings resulted in deescalation of axillary surgery for men and women with comparable OS (male HR 0.69, 95% CI 0.33-1.45). Uptake of clinical trial results for men with breast cancer often mirrors that for women, despite exclusion from these studies. Furthermore, when study findings were applied to eligible patients, men and women demonstrated similar survival. Observational studies can help inform the potential application of study findings to this unique population and improve patient enrollment in clinical trials.
Sections du résumé
BACKGROUND
BACKGROUND
Men represent a small proportion of breast cancer diagnoses, and they are often excluded from clinical trials. Current treatments are largely extrapolated from evidence in women. We compare practice patterns between men and women with breast cancer following the publication of several landmark clinical trials in surgery.
PATIENTS AND METHODS
METHODS
Patients with invasive breast cancer (2004-2015) from the National Cancer Data Base were identified; subcohorts were created based on eligibility for NSABP-B06, CALGB 9343, and ACOSOG Z0011. Practice patterns were stratified by gender and compared. Cox proportional hazards regression analyses were utilized to estimate the association between OS and gender.
RESULTS
RESULTS
Of the 1,664,746 patients identified, 99% were women and 1% were men. Among NSABP-B06 eligible men, mastectomy rates did not change (consistently ~ 80%), and their adjusted OS was minimally worse compared with women (HR 1.19, 95% CI 1.11-1.28). Following publication of CALGB 9343, omission of radiation after lumpectomy was less likely in men and lagged behind that of women, despite similar OS (male HR 0.92, 95% CI 0.59-1.44). Application of ACOSOG Z0011 findings resulted in deescalation of axillary surgery for men and women with comparable OS (male HR 0.69, 95% CI 0.33-1.45).
CONCLUSIONS
CONCLUSIONS
Uptake of clinical trial results for men with breast cancer often mirrors that for women, despite exclusion from these studies. Furthermore, when study findings were applied to eligible patients, men and women demonstrated similar survival. Observational studies can help inform the potential application of study findings to this unique population and improve patient enrollment in clinical trials.
Identifiants
pubmed: 32705510
doi: 10.1245/s10434-020-08901-z
pii: 10.1245/s10434-020-08901-z
pmc: PMC7554146
mid: NIHMS1619865
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4720-4729Subventions
Organisme : NCI NIH HHS
ID : K08 CA241390
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NIH HHS
ID : P30CA014236
Pays : United States
Organisme : NIH HHS
ID : 1K08CA241390
Pays : United States
Références
Clin Breast Cancer. 2020 Jun;20(3):e309-e314
pubmed: 32171701
J Clin Oncol. 2010 Apr 20;28(12):2114-22
pubmed: 20308661
Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):747-52
pubmed: 24138917
Ann Surg Oncol. 2020 Oct;27(10):3605-3611
pubmed: 32472417
Jpn J Clin Oncol. 2013 Jan;43(1):22-7
pubmed: 23159765
Ann Oncol. 2018 Feb 1;29(2):405-417
pubmed: 29092024
N Engl J Med. 1985 Mar 14;312(11):665-73
pubmed: 3883167
BMC Cancer. 2011 Aug 04;11:335
pubmed: 21816051
Clin Breast Cancer. 2018 Oct;18(5):e997-e1002
pubmed: 30007834
Ann Surg Oncol. 2019 Nov;26(12):3939-3944
pubmed: 31250345
Ann Surg Oncol. 2012 Oct;19(10):3199-204
pubmed: 22766989
Ann Surg Oncol. 2019 Jul;26(7):2144-2153
pubmed: 30761438
JAMA. 2017 Sep 12;318(10):918-926
pubmed: 28898379
Cancer. 2004 Sep 15;101(6):1302-10
pubmed: 15316944
Breast Cancer Res Treat. 2018 Dec;172(3):539-544
pubmed: 30187168
JAMA. 2011 Feb 9;305(6):569-75
pubmed: 21304082
Ann Oncol. 2013 Feb;24(2):370-376
pubmed: 23051951
Breast Cancer Res Treat. 2019 Jan;173(1):37-48
pubmed: 30267249
World J Surg. 2012 Jul;36(7):1475-9
pubmed: 22350481
J Am Coll Surg. 2013 Mar;216(3):428-37
pubmed: 23357724
Future Oncol. 2019 Jan;15(2):167-180
pubmed: 30088776
Ann Surg Oncol. 2018 Oct;25(10):3019-3029
pubmed: 29978365
Crit Rev Oncol Hematol. 2017 May;113:283-291
pubmed: 28427518
Endocr Relat Cancer. 2019 Oct;26(10):779-794
pubmed: 31340200
N Engl J Med. 2002 Oct 17;347(16):1233-41
pubmed: 12393820
J Clin Oncol. 2020 Jun 1;38(16):1849-1863
pubmed: 32058842
Rev Esp Med Nucl Imagen Mol. 2018 May - Jun;37(3):146-150
pubmed: 29246402
Breast Cancer Res Treat. 2020 Apr;180(2):471-479
pubmed: 32040687
Clin Breast Cancer. 2014 Oct;14(5):371-7
pubmed: 24742826
Breast Care (Basel). 2020 Feb;15(1):14-20
pubmed: 32231493
J Clin Oncol. 2013 Jul 1;31(19):2382-7
pubmed: 23690420
JCO Oncol Pract. 2020 Aug;16(8):e839-e843
pubmed: 32091951
Isr Med Assoc J. 2020 Mar;22(3):160-163
pubmed: 32147980
Acta Oncol. 2010 Apr;49(3):322-7
pubmed: 20397767
N Engl J Med. 2018 Jun 14;378(24):2311-2320
pubmed: 29897847
JAMA Oncol. 2017 Dec 1;3(12):1722-1728
pubmed: 28241198
Ann Surg Oncol. 2019 Jun;26(6):1604-1612
pubmed: 30737668
Ann Oncol. 2013 Jun;24(6):1434-43
pubmed: 23425944
Lancet Oncol. 2010 Oct;11(10):927-33
pubmed: 20863759
N Engl J Med. 2004 Sep 2;351(10):971-7
pubmed: 15342805